La lactate déshydrogénase A, une cible potentielle encore inexploitée (notice n° 681364)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04526cam a2200361 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121203249.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Robert, Jacques |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | La lactate déshydrogénase A, une cible potentielle encore inexploitée |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2023.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 2 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Plusieurs travaux récents ont fait état de l’association, dans plusieurs types de cancers, entre l’agressivité de ces cancers et l’expression d’un des enzymes chargés de l’interconversion entre pyruvate et lactate dans la dernière étape de la glycolyse, la lactate déshydrogénase A (LDHA). Cette dernière privilégie la conversion du pyruvate en lactate, alors que la lactate déshydrogénase B (LDHB) privilégie la réaction inverse et ne semble pas, elle, associée à l’agressivité des cancers comme la LDHA. Plusieurs inhibiteurs plus ou moins spécifiques de la LDHA ont été identifiés mais aucun essai clinique ne semble avoir été entrepris à ce jour. Nous avons réalisé une étude préliminaire utilisant la base de données du Cancer Genome Atlas (TCGA) afin de voir s’il était possible de confirmer l’association entre l’agressivité des cancers les plus graves et le niveau d’expression des gènes LDHA et LDHB, le critère retenu pour évaluer l’agressivité au niveau clinique étant la survie globale des patients. Un lien significatif entre la survie globale et un niveau d’expression faible du gène LDHA a été noté dans les adénocarcinomes pancréatiques et les glioblastomes, mais pas dans les carcinomes bronchopulmonaires, adénocarcinomes et carcinomes épidermoïdes, ni dans les cancers mammaires ou colorectaux. En outre, une expression élevée du gène LDHB est associée à un pronostic favorable dans les glioblastomes. Les données de la littérature, confortées par notre étude, suggèrent que la LDHA est une cible potentielle pour un développement thérapeutique en oncologie, au moins pour les adénocarcinomes pancréatiques et les glioblastomes, à condition que les molécules sélectionnées soient suffisamment sélectives de la LDHA. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Several recent studies have reported the association, for several types of cancers, between cancer aggressiveness and the expression of one of the enzymes, lactate dehydrogenase A (LDHA), responsible for the interconversion between pyruvate and lactate as the last step of glycolysis. LDHA favours the conversion of pyruvate to lactate, while lactate dehydrogenase B (LDHB) favours the opposite reaction. Moreover, unlike LDHA, LDHB does not appear to be associated with aggressiveness of cancers. Several more or less specific LDHA inhibitors have been identified but no clinical trial seems to have been undertaken to date. We carried out a preliminary study using The Cancer Genome Atlas (TCGA) database to analyse the association between the aggressiveness of the most lethal cancers and the level of expression of LDHA and LDHB genes; the criterion used to assess aggressiveness at the clinical level being overall survival of patients. A significant link between overall survival and a low level of expression of the LDHA gene was noted in pancreatic adenocarcinomas and glioblastomas, but not in bronchopulmonary carcinomas, adenocarcinomas or squamous cell carcinomas, nor in breast or colorectal cancers. Furthermore, high expression of the LDHB gene was associated with a favourable prognosis in patients with glioblastomas. Data in the literature, supported by our study, suggest that LDHA is a potential target for therapeutic development in oncology, at least for pancreatic cancer and glioblastoma, provided that the molecules chosen are sufficiently selective for LDHA. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Cancer Genome Atlas |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | . |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | glioblastomes |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | in silico |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cancers du pancréas |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | (TCGA) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lactate déshydrogénases A et B |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | recherche |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | glioblastomas |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lactate dehydrogenases A and B |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | in silico |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | research |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Cancer Genome Atlas (TCGA) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pancreatic cancers |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Le Morvan, Valérie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fessart, Delphine |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 9 | 5 | 2023-09-04 | p. 257-265 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2023-5-page-257?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2023-5-page-257?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux